Marinomed Biotech AG (93Z) Stock Price & Analysis
93Z Stock Chart & Stats
- Day’s Range
- EUR 3.76 - EUR 3.76
- 52-Week Range
- EUR 3.54 - EUR 19.93
- Previous Close
- EUR 3.76
- Volume
- N/A
- Average Volume (3M)
- 3
- Market Cap
- EUR 9.20M
- Enterprise Value
- EUR 45.78M
- Total Cash (Recent Filing)
- EUR 911.50K
- Total Debt (Recent Filing)
- EUR 29.09M
- Price to Earnings (P/E)
- 0.5
- Beta
- 0.36
- Next Earnings
- Apr 21, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
93Z FAQ
What was Marinomed Biotech AG’s price range in the past 12 months?
What is Marinomed Biotech AG’s market cap?
When is Marinomed Biotech AG’s upcoming earnings report date?
How were Marinomed Biotech AG’s earnings last quarter?
Is Marinomed Biotech AG overvalued?
Does Marinomed Biotech AG pay dividends?
What is Marinomed Biotech AG’s EPS estimate?
How many shares outstanding does Marinomed Biotech AG have?
What happened to Marinomed Biotech AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Marinomed Biotech AG?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Marinomed Biotech AG
Marinomed Biotech AG is an Austrian-based biopharmaceutical firm dedicated to developing therapeutic solutions for viral and immunological conditions, with its market presence spanning across Austria, other European nations, and globally. Their comprehensive product pipeline includes Budesolv, which addresses allergic rhinitis and autoimmune gastritis, and Tacrosolv, currently undergoing Phase II clinical trials for anterior inflammatory eye diseases. Also featured in their development are Carravin, designed to alleviate nasal congestion, and Inhaleen, which is in Phase I clinical evaluation for viral pneumonia. Additionally, the company offers Carragelose, a range of products like nasal and throat sprays and lozenges, all formulated to combat viral respiratory infections. Established in 2006, the company was initially named Marinomed Biotechnologie GmbH, adopting its current name, Marinomed Biotech AG, in June 2017, and is headquartered in Korneuburg, Austria.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andreas Grassauer
- Employees
- 32
- Website
- www.marinomed.com
- Address
- Hovengasse 25, Korneuburg, NI, 2100, AT
Marinomed Biotech AG (93Z) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 1 | 13 |
| Technical Analysis | 3 | 1 | 3 |
| Moving Averages | 2 | 0 | 10 |
